

# BMJ Open

## A qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

Journal:	BMJ Open
Manuscript ID	bmjopen-2016-012934
Article Type:	Research
Date Submitted by the Author:	03-Jun-2016
Complete List of Authors:	Bernays, Sarah; London School of Hygiene and Tropical Medicine, Paparini, Sara; London School of Hygiene and Tropical Medicine, Seeley, Janet; MRC/UVRI Uganda Research Unit On AIDS, ; London School of Hygiene and Tropical Medicine, Namukwaya Kihika, Stella; MRC/UVRI Uganda Research Unit On AIDS Gibb, Diana; MRC Clinical Trials Unit Rhodes, Tim; London Schoool of Hygiene and Tropical Medicine
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Paediatrics
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, PAEDIATRICS, Anthropology < TROPICAL MEDICINE

SCHOLARONE™  
Manuscripts

**A qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy):  
is it acceptable to young people living with HIV?**

Sarah Bernays  
Lecturer Medical Sociology  
London School of Hygiene and Tropical Medicine  
Social and Environmental Health Research  
Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

Sara Paparini  
Research Fellow  
London School of Hygiene and Tropical Medicine  
Social and Environmental Health Research  
Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

Janet Seeley (corresponding author)  
Professor of Anthropology and Health  
London School of Hygiene and Tropical Medicine  
Global Health and Development  
Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom;  
&  
Head of Social Science Programme  
MRC/UVRI Uganda Research Unit on AIDS  
Social Science Programme  
P.O. Box 49  
Plot 51-59 Nakiwogo Road  
Entebbe  
Uganda  
Email [Janet.seeley@lshtm.ac.uk](mailto:Janet.seeley@lshtm.ac.uk) or [janet.seeley@rcuganda.org](mailto:janet.seeley@rcuganda.org)  
Telephone 0207 958 8268

Stella Namukwaya Kihika  
Social Scientist  
MRC/UVRI Uganda Research Unit on AIDS  
Social Science Programme

P.O. Box 49  
Plot 51-59 Nakiwogo Road  
Entebbe  
Uganda

Diana Gibb  
Professor of Epidemiology and Programme Leader of the Paediatric Programme  
MRC Clinical Trials Unit at UCL  
Aviation House  
125 Kingsway  
London  
WC2B 6NH  
United Kingdom

Tim Rhodes  
Professor of Public Health Sociology  
London School of Hygiene and Tropical Medicine  
Social and Environmental Health Research  
Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

**ABSTRACT**

**Objectives** A qualitative sub-study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off) with continuous EFV-based antiretroviral therapy (CT) in children and young people (aged 8-24) living with HIV with viral load <50c/ml to examine adaptation, acceptability and experience of SCT to inform intervention recommendation and development.

**Setting** Paediatric HIV clinics in UK (2), Ireland (1), USA (1) and Uganda (1).

**Participants** All BREATHER trial participants who were over the age of 10 and aware of their HIV diagnosis were invited to participate. 43 young people from both arms of the BREATHER trial (26 females and 17 males; 40% of the total trial population in the respective sites; age range 11-23) gave additional consent to participate in the qualitative study.

**Results** Young people from both trial arms discussed initial concerns about the impact of SCT on their health and adherence, which decreased over the early months in the trial. Young people randomised to SCT reported preference for SCT compared to CT pre-trial. Attitudes to SCT did not vary greatly by gender or country. Once short-term adaptation challenges were overcome, SCT was positively described as reducing impact of side-effects, easing the pressure to carry and remember medication, and enabling more weekend social activities. Young people reported frequent medication side effects and occasional missed doses that they had rarely voiced to clinical staff. Participants liked SCT by trial end but were concerned that peers who had most problems adhering could find SCT disruptive and difficult to manage.

**Conclusions** To realise the potential of SCT (and mitigate possible risks of longer interruptions) careful dissemination and communication post-trial is needed. SCT should be provided alongside a package of monitoring, support and education over 3 months to allow adaptation.

**Strengths and limitations of the study**

- Including a qualitative study in the trial has enriched our understanding of the impact and influence of SCT on young people's experiences of adherence. Understanding their perspectives and experiences is thus crucial for the intervention to be effective beyond the trial.

- By specifically acknowledging adherence challenges in childhood and adolescence, if framed thoughtfully, healthcare staff can use SCT to show a greater contextual understanding about the reasons why and ways in which treatment can get disrupted.
- A key limitation of our study is the narrow population upon which these findings are based (relying on those agreeing to participate in the clinical trial and then also in the qualitative sub-study).
- Being in the trial may in itself have been conducive to better adherence, due to the increased support and monitoring in the study, particularly in contexts with little or no routine access to this level of care.

**Key words:** HIV, antiretroviral therapy, adolescents, clinical trial, qualitative

**Word count (main text):** 3021

INTRODUCTION

Rates of antiretroviral therapy (ART) adherence tend to be lower amongst young people (10-24) living with HIV compared with their adult counterparts in all settings, despite important geographical variations.[1-3] Multiple social aspects of adherence for the paediatric HIV population need to be taken into consideration alongside the specific contexts of local HIV epidemics.[4] Lack of disclosure of their HIV status and commonly insufficient discussions about the implications of HIV and ART often fail to adequately support young people’s ongoing adherence. Limited control over their living environments and secrecy surrounding HIV and treatment-taking represent significant barriers to adherence.[5-8] Treatment fatigue in facing a lifetime of ART is considered an important reason for poor adherence amongst young people living with HIV as with other long-term conditions,[9-11] although little HIV research investigates this from the perspectives of young people themselves.

Treatment interruption interventions, including Short-Cycle Therapy (SCT), aim to encourage long-term adherence by offering patients regulated time off medication. In this paper, we report on the findings from a qualitative study undertaken as part of BREATHER (PENTA 16). BREATHER is a global, Phase II, randomised, multi-centre, non-inferiority trial testing the efficacy of SCT (five days on/ two days off) for young people living with HIV (aged 8-24) on an efavirenz-based combination.[12] Amongst the inclusion criteria for the trial were: having an undetectable viral load and being on an efavirenz-based combination for the prior 12 months.

The qualitative sub-study aimed to explore the experiences of SCT and broader issues with treatment and care for a sample of trial participants (aged 10-24) through

the use of repeat interviews. As SCT is a behavioural intervention relying on self-administered ART and self-reported adherence, the qualitative study elucidated the range of factors shaping young people's adherence and their perspectives on SCT, to inform the design of any potential SCT roll-out. Sustained success of an intervention such as SCT relies not only on it being clinically *efficacious* but also *effective* for the people involved.[13] It is thus vital to understand the acceptability of SCT for young people themselves and how it interacts with their adherence efforts.

## METHODOLOGY

This is a multi-country, longitudinal, mixed-methods qualitative study taking place in the UK, Ireland, USA and Uganda, with repeat individual semi-structured interviews and focus group discussions with young people taking part in the BREATHER trial and their caregivers. In this article we report on the first two waves of interviews in all of the qualitative study sites, which focused on participants' experience of SCT during the trial.

All young people recruited into the BREATHER trial in the UK, Ireland, Uganda and the USA, aged 10-24, were eligible to participate in the qualitative study. This was subject to self-awareness of HIV infection (for at least six months), since not all trial participants were aware of their HIV positive status. Participants under the age of 10 were not deemed old enough to be able to meaningfully take part in in-depth interviews. In addition to consent procedures for the clinical trial, we carried out separate consent and assent procedures for the qualitative study as appropriate. Participants invited to the qualitative study came from both the SCT and the continuous therapy (CT) arms of the BREATHER trial. The study received all the

necessary ethics approvals. Audio-recorded data was transcribed verbatim and translated into English where appropriate. Personally identifying details have been removed.

The study adopted a grounded analytic approach to qualitative thematic analysis, using systematic case comparison and negative case analysis throughout.[14-15] This involves iterative comparison of codes extracted from the multiple interview data for each research participant. These are corroborated with the use of 'negative cases', whereby the analysis is built by including instances in the data that differ or counteract themes found in the majority of cases.

The qualitative study represents an important contribution towards the involvement of trial participants in the development of the intervention. In the focus groups discussions (currently on-going) we are exploring participants' views on how the trial results could best be disseminated. We are also collecting their perspectives on the measures that should be in place for a potential roll-out of the intervention at the end of the BREATHER trial.

**SAMPLE**

Repeat interviews were conducted with 43 young people. The qualitative sample in each site reflects the diversity of the trial population in terms of sex, age and ethnicity. Twenty-six young people were recruited in Uganda from one clinic (Joint Clinical Research Centre, Kampala), seven in the UK and Ireland from three clinics (hospitals in London, Nottingham and Dublin) and ten in the USA from one clinic (St. Jude's Children's Research Hospital, Memphis). We report combined data on the



small samples in UK and Ireland to avoid participant identification. Recruitment response and retention through the repeated phases of the qualitative study was high: overall we included approximately 40% of the trial participants (only of those who were 10 years and over) in the countries where the study was conducted (Table 1). The qualitative study sample also represented a significant proportion of the sample for the BREATHER trial in all countries (43/199 trial participants overall).

**Table 1 Qualitative sample overview**

Country	No.	Male	Female	On SCT	On CT	Switched or Left trial	Age range	Response rate
Uganda	26	12	14	14	10	2 (to CT)	11 – 22	26/66
UK (& Ireland)	7	5	2	4	3	-	12 – 17	7/23
USA	10	9	1	4	5	1 (from trial)	18 – 22	10/14
<b>Total</b>	<b>43</b>	<b>26</b>	<b>17</b>	<b>22</b>	<b>18</b>	<b>3</b>	<b>11 – 22</b>	<b>43/103</b>

## FINDINGS

### *Early concerns about SCT*

Overall, participants described a positive SCT experience, a preference for SCT, and those on SCT wished to continue with their new regimen. This strongly suggests SCT was acceptable to most participants on the intervention arm, with no difference by age, gender or country. Around the time of randomisation and in the early stages of the trial, young people from both arms discussed anxieties about the possible impact of SCT on their health and adherence patterns:

*"I thought that it [SCT] would be harmful ... Because I was taking a break yet I was not used to that." (Uganda, SCT arm)*

Some worried they might mistake or forget the days on and the days off. They were concerned that any mistakes would damage their health, and that they could not predict changes in their own behaviour or in their bodies':

*"[It] was bothering me just a little bit to take off two days ... I might miss an extra day, because then I might be scared that something might go on and my body might change a certain way." (USA, CT arm)*

**Adaptation to SCT**

Concerns decreased over the first few months in the trial when participants did not observe any explicit adverse effects. However, almost all of the participants on the SCT arm reported challenges in initially adapting to the new routine:

*"Oh, that was hectic ... when I first started the study, I think the first week I think I took it on a day that I wasn't supposed to take it because I'm so used to it. But now I'm used to it." (USA, SCT arm)*

Many described finding it difficult to deliberately miss treatment, when they had consistently been encouraged to take their pills every day:

*"Because being so used to taking it seven days a week and then now they're saying I can take two days off, it's like a slight change and if you don't get*

1  
2  
3 *your mind focused ... basically it's like when you're so used to something and*  
4  
5 *then you're trying to change it, it takes time."* (USA, SCT arm)  
6  
7  
8  
9

10 The adaptation period was relatively short, and young people tended to become  
11 used to the new routine within two-to-eight weeks. Once they had adjusted to SCT,  
12 many reported finding it 'liberating' to not have to remember, carry and take  
13 treatment at the weekends. This enabled them to socialise more, without worrying  
14 about finding a private space to take pills:  
15  
16  
17  
18  
19

20  
21  
22  
23 *"It's actually very good because I can get some time for me and actually not*  
24 *think of the drugs ... I also get a day I am free to do whatever I want at any*  
25 *time I want, go out wherever I want to, stay over the weekend and then take*  
26 *them [drugs] when I am back on Monday. So it's easier and good."* (Uganda,  
27  
28  
29  
30  
31  
32 SCT arm)  
33  
34  
35

### 36 **Missing doses and ART side-effects**

37  
38 SCT brought respite also because some participants felt that there was a 'legitimate'  
39 way to miss doses. They were reassured by the trial that their medication had  
40 continued to be effective even if they had not been adhering 100% to their regimen:  
41  
42  
43  
44  
45  
46

47 *"If you don't have a break you may forget to take drugs like on a Saturday or*  
48 *Sunday but if you are supposed to have a break it is acceptable."* (Uganda,  
49  
50  
51  
52 SCT arm)  
53  
54  
55  
56  
57  
58  
59  
60

SCT thus eased the pressure to *never* miss any treatment. Knowing they could have the weekends off, and worrying about missing too many cumulative doses, many were instead motivated to take their treatment diligently for the remainder of the week:

*"I'd probably have been a bit more cautious ... you're already missing two days so ... you kind of get the impression you can't really miss another one."*  
(UK, SCT arm)

Nonetheless, although described by the clinics as 'exemplary adherers' with undetectable viral loads, participants did report missing doses occasionally and intermittently – when on CT or outside of the prescribed SCT days. Stable viral load results were interpreted by participants as justification to avoid reporting 'slippages' to their clinicians:

*"I try not to hide anything, it's just that I probably feel like a smidge ashamed ... because I'd have told them if they asked, but if they didn't ask then and I find out my viral load was undetectable then I just let out a sigh of relief and keep going."* (USA, SCT arm)

Similarly, young people from both randomised arms reported frequent and sometimes disabling treatment side-effects that had so far been difficult to voice in the clinic:

1  
2  
3 *"I used to take it while at school but I would feel dizzy. After taking it at*  
4 *9:30pm I could not read by 10 and would not be able to walk properly yet I*  
5 *didn't want to disturb other children so I would just lie down there."* (Uganda,  
6  
7  
8  
9  
10 SCT arm)

11  
12  
13  
14 Some participants discussed having to change the time of the day when they take  
15 their medicines, and adapt day-to-day activities to cope with side-effects:  
16  
17

18  
19  
20  
21 *"The doses at 5 I tried switching it up, when I was in school I tried switching it*  
22 *to me taking it in the morning. I can't say it wasn't really such a good idea but*  
23 *that feeling of being high at school was not the best situation, I don't like that*  
24 *at all because I mean I can't concentrate, [I] feel like I'm not really there."*  
25  
26  
27  
28  
29 (USA, CT arm)  
30  
31  
32

33  
34 Participants also reported that side-effects were not felt on the days when they did  
35 not take their medication, so SCT afforded them a welcome break. In this way, some  
36 participants reported that SCT made the experience of taking treatment more  
37  
38  
39  
40  
41 bearable:  
42  
43

44  
45 *"I don't get hot flushes on the weekends and I can stay up a little bit longer ...*  
46 *It's like your body starts getting woozy and weak and now on the weekends*  
47 *it's like, I'm just still full of energy. So it's better, much better."* (USA, SCT  
48  
49  
50  
51 arm)  
52  
53  
54

## 55 56 **Keeping the secret** 57 58 59 60

We found that young people often miss doses when they are in social situations which present a risk of being seen taking their treatment. Hence participants emphasised that the many benefits of SCT stemmed from reducing the visibility of ART in social situations. This is illustrative of young people's broader concerns, which underpin non-adherence at certain times:

*"It becomes tiresome to take the drugs every day because there are times when you are away from home or amongst people who don't know about you ... So whoever sees you becomes eager to know what you are taking or what you are hiding. In my opinion having to rest is good because sometimes you may be amongst people like on a Saturday or Sunday but you are not going to take drugs so no one will get to know about your health."* (Uganda, SCT arm)

**SCT as 'progress' and reward**

SCT - and the BREATHER trial more generally - also symbolised scientific progress to young people, a step towards a foreseeable future of better HIV therapy, when they might be able to take even less medication or a cure for HIV may be found. This may be particularly valuable for those initiated onto treatment at a very young age:

*"The thought of having to take something for the rest of your life for seven days a week it's kind of nerve wracking, but when you know that you have that break it's better ... it tells the person that there's hope."* (USA, SCT arm)

**Other young people and SCT**

Despite their own positive overall experiences of SCT, many participants, from both arms, were concerned that the idea of SCT could disrupt the clarity of the adherence messages young people are given. They felt that SCT may inadvertently indicate to young people that missing further days/doses was acceptable, when instead this was only advisable under specific conditions:

*"It might be [dangerous] because some people might see it as like, why should I take it every day? Maybe I should just go ahead and stop taking every day and skip two days or three days, just to clean me out or something like that."* (USA, CT arm)

Many were thus concerned about what other positive young people might do once the trial results are made public:

*"I do think for some people if they do find out about the information it may be OK if they do it but in the back of my mind I'm still worried because ... if some people aren't undetectable and they try to do the Short-Cycle Therapy that would really affect them."* (USA, CT arm)

## DISCUSSION

Findings from this qualitative study indicate that those on the SCT arm, after taking some time to adapt, expressed a preference for taking the weekends off treatment, which suggests that SCT was acceptable to them. Although preferred to continuous therapy by those in the trial, SCT may not be a viable option for everyone, because



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

even ‘exemplary adherers’ like the young people in our study encountered initial challenges in adapting to the new routine. The study highlighted patterns of non-disclosure of adherence behaviours common amongst young people living with HIV.[16-17] However, our data have further illustrated how young people use clinical indicators to gauge whether to share information about ‘slippages’, and to justify non-disclosure of adherence issues. They interpret an undetectable viral load as a demonstration that recent missed doses are not significant. The extent and impact of medication side-effects were also consistently under-reported to clinicians, and possibly within the trial. Some participants had come to perceive these side effects as inevitable and not worthy of mentioning to clinic staff. Further research with young people on efavirenz-based medication is urgently needed to understand how side-effects might affect their adherence and their perceptions of themselves, health and HIV.[18-19]

A key limitation of our study is the narrow population upon which these findings are based (relying on those agreeing to participate in the clinical trial and then also in the qualitative sub-study). Also, being in the trial may in itself have been conducive to better adherence, due to the increased support and monitoring in the study, particularly in contexts with little or no routine access to this level of care. So far we have not explored the acceptability of SCT amongst those who refused to take part in the trial or were not eligible. It will be vital to include these young people in the future to address acceptability of SCT more broadly and robustly.

Including a qualitative study in the trial has enriched our understanding of the impact and influence of SCT on young people’s experiences of adherence. This is likely to



1  
2  
3 contribute to the wider success of the intervention, by informing how SCT might be  
4 rolled-out outside of trial conditions. The intervention relies on young people to  
5 change the ways in which they take their treatment and they adhere to the structured  
6 two-days interruption. Understanding their perspectives and experiences is thus  
7 crucial for the intervention to be effective beyond the trial.  
8  
9  
10  
11  
12  
13

14  
15  
16 Findings about both adherence and side-effects differ between what young people  
17 reported in the qualitative interviews, data in the quantitative adherence surveys  
18 during the trial, and the reporting of treatment-adverse events in the clinical  
19 database. We do not consider these differences in datasets to indicate more or less  
20 accuracy of the findings from each method. Rather, we suggest they might be  
21 usefully triangulated and integrated in further study designs. Quantitative measures  
22 in isolation might be unable to account for how self-reported adherence is influenced  
23 by perceptions, or experiences, of how admissions of non-adherence are received in  
24 the clinic.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37  
38 SCT thus presents a unique opportunity to change the conversation about ART with  
39 young people. By specifically acknowledging adherence challenges in childhood and  
40 adolescence, if framed thoughtfully, healthcare staff can use SCT to show a greater  
41 contextual understanding about the reasons why and ways in which treatment can  
42 get disrupted. Our findings also suggest that SCT could be used as a 'reward' for  
43 those who can manage to adhere well, sustaining them on the days 'on' ART. In  
44 addition, SCT could be an incentive for those who would not yet qualify for SCT in  
45 their present situation to put more effort into taking treatment and lowering viral load.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 Thoughtful planning and framing of SCT to young people is necessary for these

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

potential benefits to be realised. However, as a patient-managed strategy, participants felt that SCT could also pose significant risk to other young people who may independently take treatment breaks under inappropriate conditions and without assessment and monitoring. This provides further evidence of the need for careful dissemination and communication post-trial.

In conclusion, the initial challenges described by so many participants need to be taken into serious consideration when planning any further intervention. The adaptation period, although different for different participants, was generally only short-lived but it should not be under-estimated. Provided early adjustments are carefully managed through a tailored brief support programme, the study has shown that SCT could be successfully transformed into a welcome treatment option for young people living with HIV.

## ACKNOWLEDGEMENTS

The authors wish to thank all the participants in the study for the time and valuable information that they shared with us. We thank the BREATHER Clinical Trial Teams at the Clinical Trials Unit at University College London, for their significant contribution to this qualitative research. We also wish to acknowledge and thank our funders for their financial support.

## COMPETING INTERESTS

The authors declare that they have no competing interests.

## FUNDING

The BREATHER qualitative study was funded by the Economic and Social Research Council [RES-062-23-2308] and the NIHR Health Technology Assessment Programme [08/53/25]. The funders had no direct role in study design, data collection, analysis, interpretation, report writing, or the decision to submit for publication. The corresponding author had access to all data and responsibility for submission for publication.

## AUTHOR CONTRIBUTIONS

SB was lead coordinator with oversight of all research activities was study. SB was co-investigator on the study with TR and JS. SB, TR and JS are guarantors for the study. SB led study design with contribution from all authors. SB and JS were responsible for study management. DG, PI for the clinical trial, coordinated between the qualitative sub-study team and the clinical trial team. SB directly carried out fieldwork in the US, UK and Ireland. SNK carried out fieldwork in Uganda. JS supervised the Uganda study site. SB, SP and SNK carried out the analysis. All authors interpreted the results of the analysis. SB and SP prepared the first draft of this paper. All authors reviewed manuscript drafts, revised for important intellectual content, and approved the final version. All authors, external and internal, had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

## ETHICAL APPROVAL

The study obtained ethics approval from the following:

- LSHTM Observational. Interventions Research Ethics Committee institutional review -Ref- 5897. This covered all three sites, UK, Uganda and USA.
- The Medicines for Human Use (Clinical Trials) Regulations (MHRA)- Ref- 27505/0005/001-0005
- National Research Ethics Service (REC), The Joint UCL/ UCLH Committees on the Ethics of Human Research (Committee A)- Ref- 10/H0714/8
- The Uganda National Council for Science and Technology- Ref- SS-2641.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- Joint Clinical Research Centre Ethics Committee no number (reference JCRC-IRB/REC)
- St Jude's Children's Research Hospital- Institutional Review Board 29.

All participants gave informed consent before taking part.

The lead author (SB) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

For peer review only

## REFERENCES

- 1 Kim SH, Gerver SM, Fidler S, Ward H. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *AIDS (London, England)* 2014; **28**(13): 1945–1956. doi: 10.1097/QAD.0000000000000316
- 2 Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. *The Lancet Infectious Diseases* 2014; **14**(7): 627–39. doi: 10.1016/S1473-3099(13)70363-3.
- 3 Vreeman RC, Gramelspacher AM, Gisore PO, Scanlon ML, Nyandiko WM. Disclosure of HIV status to children in resource-limited settings: a systematic review. *Journal of the International AIDS Society* 2013; **16**(1): 18466. doi: 10.7448/IAS.16.1.18466
- 4 Bernays S, Jarrett P, Kranzer K, Ferrand RA. Children growing up with HIV infection: the responsibility of success. *Lancet* 2014; **383**(9925): 1355–7.
- 5 Bernays S, Seeley J, Rhodes T, Mupambireyi Z. What am I 'living' with? Growing up with HIV in Uganda and Zimbabwe. *Sociology of Health & Illness* 2015; **37**(2): 270–83.
- 6 Fielden SJ, Chapman GE, Cadell S. Managing stigma in adolescent HIV: silence, secrets and sanctioned spaces. *Culture, Health & Sexuality* 2011; **13**(03): 267–81.
- 7 Vreeman RC, Nyandiko WM, Ayaya SO, Walumbe EG, Marrero DG, Inui TS. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral

therapy adherence, child well-being, and social relationships in a resource-limited setting. *AIDS Patient Care and STDs* 2010; **24**(10): 639–49.

Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. *Pediatrics* 2006; **118**(6): e1745–57. doi: 10.1542/peds.2006-0493

Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. *BMC health services research* 2014; **14**(1): 201. doi: 10.1186/1472-6963-14-201

Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. *Current HIV/AIDS Reports* 2009; **6**(4): 194–200.

MacDonell K, Naar-King S, Huszti H, Belzer M. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. *AIDS and Behavior* 2013; **17**(1): 86–93.

Butler K on behalf of the BREATHER trial team: ART with weekends off is non-inferior to continuous ART in young people on EFV+2 NRTI. CROI 2015, Seattle, USA, Feb 23 -26 2015. Oral presentation abstract 38LB.

Kippax S, Reis E, de Wit J. Two sides to the HIV prevention coin: efficacy and effectiveness. *AIDS Education and Prevention* 2011; **23**(5): 393–6.

Charmaz K. *Constructing Grounded Theory*. London: Sage; 2006.

- 1  
2  
3 15 Strauss AL, Corbin JM. Basics of Qualitative Research: *Grounded Theory*  
4 *Procedures and Techniques*. Newbury Park, California: Sage Publications; 1990.  
5  
6  
7  
8  
9 16 Kawuma R, Bernays S, Siu G, Rhodes T, Seeley J. 'Children will always be  
10 children': Exploring perceptions and experiences of HIV-positive children who may  
11 not take their treatment and why they may not tell. *African Journal of AIDS Research*  
12 2014; **13**(2): 189–95.  
13  
14  
15  
16  
17  
18 17 Bernays S, Paparini S, Gibb D, Seeley J. When information does not suffice:  
19 young people living with HIV and communication about ART adherence in the clinic.  
20 *Vulnerable Children and Youth Studies* 2015; Dec 31: 1–9. doi:  
21 10.1080/17450128.2015.1128581  
22  
23  
24  
25  
26  
27  
28 18 Persson A, Newman C. Potency and vulnerability: Troubled 'selves' in the  
29 context of antiretroviral therapy. *Social Science & Medicine* 2006; **63**(6): 1586–96.  
30  
31  
32  
33  
34  
35 19 Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM. The  
36 impact of specific HIV treatment-related adverse events on adherence to  
37 antiretroviral therapy: A systematic review and meta-analysis. *AIDS Care* 2013;  
38  
39  
40  
41 **25**(4): 400–14.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



# BMJ Open

## A qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

Journal:	BMJ Open
Manuscript ID	bmjopen-2016-012934.R1
Article Type:	Research
Date Submitted by the Author:	14-Nov-2016
Complete List of Authors:	Bernays, Sarah; London School of Hygiene and Tropical Medicine, Paparini, Sara; London School of Hygiene and Tropical Medicine, Seeley, Janet; MRC/UVRI Uganda Research Unit On AIDS, ; London School of Hygiene and Tropical Medicine, Namukwaya Kihika, Stella; MRC/UVRI Uganda Research Unit On AIDS Gibb, Diana; MRC Clinical Trials Unit Rhodes, Tim; London Schoool of Hygiene and Tropical Medicine
<b>Primary Subject Heading</b>:	HIV/AIDS
Secondary Subject Heading:	Paediatrics
Keywords:	PAEDIATRICS, Anthropology < TROPICAL MEDICINE, HIV, antiretroviral therapy

SCHOLARONE™  
Manuscripts

**A qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy):  
is it acceptable to young people living with HIV?**

Sarah Bernays  
Lecturer Medical Sociology  
London School of Hygiene and Tropical Medicine  
Faculty of Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

Sara Paparini  
Research Fellow  
London School of Hygiene and Tropical Medicine  
Faculty of Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

Janet Seeley (corresponding author)  
Professor of Anthropology and Health  
London School of Hygiene and Tropical Medicine  
Faculty of Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH

United Kingdom;

&

Head of Social Science Programme

MRC/UVRI Uganda Research Unit on AIDS

Social Science Programme

P.O. Box 49

Plot 51-59 Nakiwogo Road

Entebbe

Uganda

Email [Janet.seeley@lshtm.ac.uk](mailto:Janet.seeley@lshtm.ac.uk) or [janet.seeley@mrcuganda.org](mailto:janet.seeley@mrcuganda.org)

Telephone 0207 958 8268

Stella Namukwaya Kihika

Social Scientist

MRC/UVRI Uganda Research Unit on AIDS

Social Science Programme

P.O. Box 49

Plot 51-59 Nakiwogo Road

Entebbe

Uganda

Diana Gibb

Professor of Epidemiology and Programme Leader of the Paediatric Programme

MRC Clinical Trials Unit at UCL

Aviation House

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

125 Kingsway  
London  
WC2B 6NH  
United Kingdom

Tim Rhodes  
Professor of Public Health Sociology  
London School of Hygiene and Tropical Medicine  
Faculty of Public Health Policy  
15-17 Tavistock Place  
London WC1H 9SH  
United Kingdom

## ABSTRACT

**Objectives** A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off) with continuous EFV-based antiretroviral therapy (CT) in children and young people (aged 8-24) living with HIV with viral load <50c/ml to examine adaptation, acceptability and experience of SCT to inform intervention development.

**Setting** Paediatric HIV clinics in UK (2), Ireland (1), USA (1) and Uganda (1).

**Participants** All BREATHER trial participants who were over the age of 10 and aware of their HIV diagnosis were invited to participate. 49 young people from both arms of the BREATHER trial (31 females and 18 males; 40% of the total trial population in the respective sites; age range 11-24) gave additional consent to participate in the qualitative study.

**Results** Young people from both trial arms had initial concerns about the impact of SCT on their health and adherence, but these decreased over the early months in the trial. Young people randomised to SCT reported preference for SCT compared to CT pre-trial. Attitudes to SCT did not vary greatly by gender or country. Once short-term adaptation challenges were overcome, SCT was positively described as reducing impact of side-effects, easing the pressure to carry and remember medication, and enabling more weekend social activities. Young people on both arms reported frequent medication side effects and occasional missed doses that they had rarely voiced to clinical staff. Participants liked SCT by trial end but were

concerned that peers who had most problems adhering could find SCT disruptive and difficult to manage.

**Conclusions** To realise the potential of SCT (and mitigate possible risks of longer interruptions) careful dissemination and communication post-trial is needed. SCT should be provided alongside a package of monitoring, support and education over 3 months to allow adaptation.

**Strengths and limitations of the study**

- Including a qualitative study in the trial has enriched our understanding of the impact and influence of SCT on young people’s experiences of adherence. Understanding their perspectives and experiences is thus crucial for the intervention to be effective beyond the trial.
- By specifically acknowledging adherence challenges in childhood and adolescence, if framed thoughtfully, healthcare staff can use SCT to show a greater contextual understanding about the reasons why and ways in which treatment can get disrupted.
- A key limitation of our study is the narrow population upon which these findings are based (relying on those agreeing to participate in the clinical trial and then also in the qualitative study).
- Being in the trial may in and of itself have been conducive to better adherence, due to the increased support and monitoring in the study, particularly in contexts with little or no routine access to this level of care.

**Key words:** HIV, antiretroviral therapy, adolescents, clinical trial, qualitative

**Word count (main text):** 4303

For peer review only

INTRODUCTION

Rates of antiretroviral therapy (ART) adherence tend to be lower amongst young people (10-24) living with HIV compared with their adult counterparts in all settings, despite important geographical variations.[1-3] Multiple social aspects of adherence for the paediatric HIV population need to be taken into consideration alongside the specific contexts of local HIV epidemics.[4] Lack of disclosure of their HIV status and, commonly, insufficient discussions about the implications of HIV and ART often fail to adequately support young people’s ongoing adherence.[5] Limited control over their living environments and secrecy surrounding HIV and treatment-taking represent significant barriers to adherence.[6-9] Treatment fatigue in facing a lifetime of ART is considered an important reason for poor adherence amongst young people living with HIV as with other long-term conditions,[10-12] although little HIV research investigates this from the perspectives of young people themselves.

We report on the findings from a qualitative study undertaken as part of BREATHER (PENTA 16). BREATHER is a global, Phase II, randomised, multi-centre, non-inferiority trial testing the efficacy of Short Cycle Therapy (SCT) (five days on/ two days off) for young people living with HIV (aged 8-24) on an efavirenz-based combination.[13] Amongst the inclusion criteria for the BREATHER trial were: having an undetectable viral load and being on an efavirenz-based combination for the prior 12 months. Treatment interruption interventions, including SCT, aim to encourage long-term adherence by offering patients regulated time off medication. The trial design to test having the weekends off treatment was informed by anecdotal evidence suggesting that managed interruptions can ameliorate the challenges of adhering continuously.[14]



The qualitative study aimed to explore the experiences of SCT, and of treatment and care more generally, among a sample of trial participants (aged 10-24). SCT is a behavioural intervention relying on self-administered ART and self-reported adherence. We used qualitative methods to elucidate whether SCT was an acceptable intervention to the target patient group and to inform any potential SCT roll-out, to ensure it is not only clinically *efficacious* but also *effective* for the people involved.[15]

## METHODOLOGY

The qualitative study employed a longitudinal, mixed-methods design and took place in the UK, Ireland, USA and Uganda. All young people recruited into the BREATHER trial in these countries, and aged 10-24, were eligible to participate in our study. This was subject to self-awareness of HIV infection (for at least six months), since not all trial participants were aware of their HIV positive status. Children under the age of 10 were not deemed old enough to participate meaningfully in our qualitative research. In addition to consent procedures for the clinical trial, we carried out separate consent and assent procedures as appropriate. The study received all the necessary ethics approvals and participants were reimbursed at rates in line with standard local research practices.

A longitudinal design was adopted. The first interview, conducted (in all three sites) towards the start of the trial explored participants' attitudes towards taking HIV treatment and whether or not this fit in with their daily lives and priorities. The second interview, conducted (in all three sites) at least nine months into the trial,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

focused on their experience of being in the trial, including their attitudes towards SCT. The third interview, conducted (only in Uganda and UK) towards the end of the trial, investigated their ongoing experience of the trial and their preferences for future treatment options. We also conducted focus group discussions (FGDs) in Uganda after the trial findings had been explained to participants by clinicians in this site. The data were collected by SB, SN and two other Ugandan researchers, none of whom were known to the participants prior to the study. Interviews and FGDs lasted between 45-120 minutes and were conducted with participants in the clinic, apart from an interview conducted in one participant's home at their request. Audio-recorded data were transcribed verbatim and translated into English where appropriate. Personal identifying details have been removed.

The topic guide for each phase included uniform key area of investigation but not a list of prescribed questions. Though the overarching focus was similar, the guides were flexible enough to ensure interviewers could adapt the form and nature of the questions to the circumstances and maturity of the individual participant.

Data analysis was conducted by all members of the research team. A grounded analytic approach to qualitative thematic analysis was adopted, using systematic case comparison.[16 17] A discussion was held after each interview to consider emerging analytical ideas and opportunities to refine the interview guide and approach. The coding was done inductively and individually developed. These preliminary codes were then exchanged amongst the team, discussed and reconciled into an agreed coding framework, which was subsequently applied to the data. We then conducted an iterative comparison of codes extracted from the

multiple interview data for each research participant. These are corroborated with the use of 'negative case' analysis, built by including instances in the data that differ or counteract emerging findings and explanations.

## SAMPLE

Repeat interviews were conducted with 43 young people. The qualitative sample in each site reflects the diversity of the trial population in terms of sex, age and ethnicity. Twenty-six young people were recruited in Uganda from one clinic (Kampala), seven in the UK and Ireland from three clinics (hospitals in London, Nottingham and Dublin) and ten in the USA from one clinic (Memphis). We report combined data on the small samples in UK and Ireland to avoid participant identification.

The only difference that we noted by site was in study recruitment and engagement. In the USA we recruited all participants who were eligible and enrolled in the trial at the time of the phase one fieldwork (numerical saturation) and in Uganda we recruited participants until we reached theoretical saturation. There were greater challenges to recruitment in the UK, both for the trial and the qualitative study. While we were unable to collect data on this, our impression is of potential research fatigue given the extent of clinical trial research conducted amongst this relatively small clinical population. Nonetheless, overall recruitment response and retention through the repeated phases of the qualitative study was high, and the qualitative study sample also represented a significant proportion of the sample for the BREATHER trial in all countries (43/199 trial participants overall).

Table 1 In-depth interview sample overview

Country	No.	Male	Female	On SCT	On CT	Switched or Left trial	Age range at phase 1	Mean Age	Response rate
Uganda	26	12	14	14	10	2 (to CT)	11 – 22	16	26/66
UK (& Ireland)	7	5	2	4	3	-	12 – 17	15	7/23
USA	10	9	1	4	5	1 (from trial)	18 – 22	20	10/14
Total	43	26	17	22	18	3	11 – 22	17	43/103

We conducted four FGDs in Uganda after the trial findings had been reported to the study participants by clinicians. At this point trial participants had moved into a follow-up phase of the trial and were continuing in their same assigned treatment arms. In addition to including a theoretically informed sub-sample of the interview sample, we invited six further trial participants, who had not previously been involved in the qualitative study, to take part in the FGDs to broaden our understanding of the acceptability of SCT across the trial patient group.

In this article, we have chosen to use only randomized arm and country of origin as identifiers for the quotes. This is to protect the anonymity and confidentiality of the small sample.

**Table 2 Focus Group Discussions sample overview**

FGD	Age range at point of FGD	Mean age	No of participants	Male	Female	SCT	CT
FGD 1	13-15	13.5	6	4	2	4	2
FGD 2	15-17	15.7	7	2	5	5	2
FGD 3	19-24	21	7	4	3	2	5
FGD 4	16-20	18	5	2	3	2	3

## FINDINGS

We report on the experiences of participants from both arms (rather than just those on SCT) to address the question of acceptability of the intervention to the patient target group. Given that they were randomly assigned to the intervention or control arm, they all had equal chance of being put onto SCT. Hence all participants had important insights to share about how they perceived SCT as an intervention for young people living with HIV. It is critical to note that we did not find significant differences in experience or attitudes to SCT by gender, age or country site. The slight differences we noted were limited to the style of accounting across countries and ages, but there was no variation by content.

Overall participants described a positive SCT experience and a preference for SCT over Continuous Therapy (CT). However, those in the SCT arm described challenges adapting to SCT in the short term. Young people from both arms discussed having initial anxieties about the impact SCT could have on their health

and adherence patterns, but these concerns decreased after the first few months in the trial.

**Early concerns about SCT**

In the early stages of the trial, young people from both arms discussed anxieties about the possible impact of SCT on their health and adherence patterns:

*“I thought that it [SCT] would be harmful ... Because I was taking a break yet I was not used to that.”* (Uganda, SCT arm)

Some worried they might mistake or forget the days on and the days off. They were concerned that any mistakes would damage their health, and that they could not predict changes in their own behaviour or in their bodies:

*“[The thought] was bothering me just a little bit to take off two days ... I might miss an extra day, because then I might be scared that something might go on and my body might change a certain way.”* (USA, CT arm)

**Adaptation to SCT**

Concerns decreased over the first few months in the trial when participants on SCT did not observe any explicit adverse effects. However, almost all the participants on the SCT arm reported challenges in initially adapting to the new routine:

*“Oh, that was hectic ... when I first started the study, I think the first week I think I took it on a day that I wasn’t supposed to take it because I’m so used to it. But now I’m used to it.”* (USA, SCT arm)

Many found it difficult to deliberately miss treatment, when they had consistently been encouraged to take their pills every day:

*“Because being so used to taking it seven days a week and then now they’re saying I can take two days off, it’s like a slight change and if you don’t get your mind focused ... basically it’s like when you’re so used to something and then you’re trying to change it, it takes time.”* (USA, SCT arm)

SCT also temporarily affected some of the participants’ autonomy in treatment taking. To adapt to their new treatment schedule, some had to reverse the independence gained by managing their own treatment, and temporarily ask for supervision from their carers after having been in sole charge of their adherence for some time. The adaptation period was relatively short, and young people tended to become used to the new routine within two-to-ten weeks.

Only one participant reported being unable to adapt to the changes brought by SCT and at their request was returned to CT.

*“It is me who even told the Doctor that I want to go out of this short cycle. Because I used to miss. If I miss I would miss even Monday.”* (Uganda, Changed back from SCT to CT arm)



All the others on SCT reported getting used to their new regimen and even finding that having two days off helped them to adhere to their medication for the remaining five days of the week. SCT thus worked both as a reminder and as a reward:

*'It [SCT] gives you the courage to take your drugs daily other than in the other days. Reason being that you will say that I have missed to take the drugs in these two days that means that in the remaining days I have to be vigilant to take the drugs such that I can have the guts of rest in these other days [two days]. (Uganda, SCT arm)*

Many reported finding it 'liberating' to not have to remember, carry and take treatment at the weekends. This enabled them to socialise more, without worrying about finding a private space to take pills:

*"I don't know what it is about those two days, but it's the best days ever (...) I can go somewhere and not have to worry about taking that pill. Sometimes when I take the pill, my stomach hurts sometimes (...) but I don't have to worry about that, and I don't have to worry about taking this big pill, and I don't got to worry about coming home at a certain time and taking it, I don't got to worry about getting up and taking it. I'm just free for those two days." (USA, SCT arm)*

*"It gave me freedom inside my heart and I saw that eeh at least here I have started to be like a normal person." (Uganda, SCT arm)*



It is important to note that the challenges in adapting to SCT only came up in the later waves of data collection, although many participants would have been going through these around the time of their first interview. They may have found it easier to identify a problem retrospectively once it had been addressed, but their confidence in what they could tell us in interviews also increased. Indeed, some also mentioned in later interviews that they did not voice their ambivalence or problems with SCT at the start of the trial for fear that they would be moved to the CT arm.

### ***Missing doses and ART side-effects***

SCT brought respite also because some participants felt that there was a 'legitimate' way to miss doses. They were reassured by the trial that their medication had continued to be effective even if they had not been adhering 100% to their regimen:

*"If you don't have a break you may forget to take drugs like on a Saturday or Sunday but if you are supposed to have a break it is acceptable."* (Uganda, SCT arm)

SCT thus eased the pressure to *never* miss any treatment. Knowing they could have the weekends off, and worrying about missing cumulative doses, many were instead motivated to take their treatment diligently for the remainder of the week:

*"I'd probably have been a bit more cautious ... you're already missing two days so ... you kind of get the impression you can't really miss another one."* (UK, SCT arm)

Nonetheless, although described by those working in the clinics as ‘exemplary adherers’ with undetectable viral loads, participants did report missing doses occasionally and intermittently – when on CT or outside of the prescribed SCT days. Participants interpreted stable viral load results as justification to avoid reporting ‘slippages’ to their clinicians:

*“I try not to hide anything, it’s just that I probably feel like a smidge ashamed ... because I’d have told them if they asked, but if they didn’t ask then and I find out my viral load was undetectable then I just let out a sigh of relief and keep going.” (USA, SCT arm)*

Similarly, young people from both randomised arms reported frequent and sometimes disabling treatment side-effects that had so far been difficult to voice in the clinic:

*“I used to take it while at school but I would feel dizzy. After taking it at 9:30pm I could not read by 10 and would not be able to walk properly yet I didn’t want to disturb other children so I would just lie down there.” (Uganda, SCT arm)*

Some participants discussed having to change the time of the day when they took their medicines, and adapt day-to-day activities to cope with side-effects:

*“The doses at 5 ... when I was in school I tried switching it to me taking it in the morning...it wasn’t really such a good idea but that feeling of being high at*

1  
2  
3 *school was not the best situation, I don't like that at all because I mean I can't*  
4  
5 *concentrate, [I] feel like I'm not really there."* (USA, CT arm)  
6  
7  
8

9  
10 Participants also reported that side-effects were not felt on the days when they did  
11 not take their medication, so SCT afforded them a welcome break. In this way, some  
12 participants reported that SCT made the experience of taking treatment more  
13 bearable:  
14  
15  
16  
17

18  
19  
20  
21 *"I don't get hot flushes on the weekends and I can stay up a little bit longer ...*  
22 *It's like your body starts getting woozy and weak and now on the weekends*  
23 *it's like, I'm just still full of energy. So it's better, much better."* (USA, SCT  
24 arm)  
25  
26  
27  
28

### 29 30 31 **Holding back 'truths' in the clinic** 32

33  
34  
35  
36 Encouragingly, most participants greatly valued their relationship with clinicians and  
37 appreciated the care and support that they received. However, this could translated  
38 into feeling under pressure be the 'ideal patient' for their clinicians, which inhibited  
39 candid discussions about adherence problems.  
40  
41  
42  
43  
44  
45

46  
47 The label of 'exemplary adherers' applied in the clinic to trial participants (based on  
48 their undetectable viral load) demonstrates inherent challenges within the clinical  
49 relationship: it is difficult to be informed about young people's adherence behaviour if  
50 they are so anxious about the consequences of being 'found out'. Further, limited  
51 disclosure of non-adherence affected young people's capacity to receive tailored  
52  
53  
54  
55  
56  
57  
58  
59  
60

adherence support. Participants said it was easier to tell the researchers in our study about their missed doses because they were not connected to the clinic and did not fear that they would "quarrel or abuse" them.

**Keeping the secret**

We found that young people often miss doses when they are in social situations that present a risk of being seen taking their treatment. Hence participants emphasised that the many benefits of SCT stemmed from reducing the visibility of ART in social situations. This is illustrative of young people's broader concerns, which underpin non-adherence at certain times:

*"It becomes tiresome to take the drugs every day because there are times when you are away from home or amongst people who don't know about you ... So whoever sees you becomes eager to know what you are taking or what you are hiding. In my opinion having to rest is good because sometimes you may be amongst people like on a Saturday or Sunday but you are not going to take drugs so no one will get to know about your health."* (Uganda, SCT arm)

**SCT as 'progress' and reward**

SCT, and the BREATHER trial more generally, also symbolised scientific progress to young people, a step towards a foreseeable future of better HIV therapy, when they might be able to take even less medication or a cure for HIV may be found. This may be particularly valuable for those initiated onto treatment at a very young age:

*'It brings hope that time will come and you stop taking even the one pill and {that one day] completely stop taking drugs' (Uganda, CT arm)*

One participant who was moved back onto the CT arm having had a spike in their viral load described their response to the trial results:

*"Because I have ever been there (on SCT). I know how it feels, all the happiness in it. So even though I was a little sad I still have hope that I will go back soon (to SCT)." (FGD, Uganda)*

### **Response to the trial findings:**

The FGD participants in Uganda were delighted by the trial results. Many described anticipating the outcome that SCT would be 'non-inferior' given their own positive experiences of the intervention, but the results further endorsed their confidence in the benefits of SCT. This suggests too that there may have been greater anxiety about SCT than had been expressed during the trial:

*"When I heard the results, it gave me more courage to adhere to the drugs and I saw that already we had reached somewhere. We are on track. And it gave me strength and I got to know that that if it was possible then other things are coming."*

*"We were so happy because when you get a break and something went wrong and you felt bad. You would get worried and wonder if it was because of missing. But when we heard it had worked we all became happy."*

Those on the CT arm were keen to begin on SCT as soon as possible. There was however an understanding of the need to stay in the same arms for the duration of the trial follow-up. No one in the qualitative study on the CT arm described informally practicing 'their own SCT' within the period of the trial. However, some FGD participants discussed being sorely tempted to switch themselves onto SCT after hearing the results. As such they were very keen that it should be rolled out soon to those satisfying the relevant clinical criteria.

*"For me I would say that it is not good to make a child get used to taking milk which you will not be able to provide. You rather not and make them get used to black tea."*

Despite their own positive overall experiences of SCT, many participants, from both arms, were concerned that the idea of SCT could disrupt the clarity of the adherence messages young people are given. Many of these young people would generally describe their own adherence as relatively good. Hence they were anxious that although SCT had helped them, those who were having greater struggles with adherence would not be able to manage the structure and discipline required to adapt to the treatment interruption.

Many were thus concerned about what other positive young people might do once the trial results are made public and felt that other young people should not be told about SCT for fear of how they might apply this to their own treatment taking without

supervision or monitoring: "They will misinterpret the study"; "They will say that let us also do what they are doing, yet they don't have all the facts."

## DISCUSSION

Findings from this qualitative study indicate that those on the SCT arm, after taking some time to adapt, expressed a preference for taking the weekends off treatment, which suggests that SCT was acceptable to them. Although preferred to CT by those in the trial, SCT may not be a viable option for everyone, because even 'exemplary adherers' like the young people in our study encountered initial challenges in adapting to the new routine.

The study highlighted patterns of non-disclosure of adherence behaviours common amongst young people living with HIV.[5 18 19] However, our data have further illustrated how young people use clinical indicators to gauge whether to share information about 'slippages', and to justify non-disclosure of adherence issues. They interpret an undetectable viral load as a demonstration that recent missed doses are not significant. The extent and impact of medication side-effects were also consistently under-reported to clinicians, and possibly within the trial. Some participants had come to perceive these side effects as inevitable and not worthy of mentioning to clinic staff. Further research with young people on efavirenz-based medication is urgently needed to understand how side-effects might affect their adherence and their perceptions of themselves, health and HIV.[20 21]

A key limitation of our study is the narrow population upon which these findings are based (relying on those agreeing to participate in the clinical trial and then also in the



qualitative sub-study). Also, being in the trial may have been conducive to better adherence, due to the increased support and monitoring in the study, particularly in contexts with little or no routine access to this level of care. So far we have not explored the acceptability of SCT amongst those who refused to take part in the trial or were not eligible. It will be vital to include these young people in the future to address acceptability of SCT more broadly and robustly.

Including a qualitative study in the trial has enriched our understanding of the impact and influence of SCT on young people's experiences of adherence. This is likely to contribute to the wider success of the intervention, by informing how SCT might be rolled-out outside of trial conditions. The intervention relies on young people to change the ways in which they take their treatment and they adhere to the structured two-days interruption. Understanding their perspectives and experiences is thus crucial for the intervention to be effective beyond the trial. Despite an increasing recognition of the pertinence of qualitative research to understand pressing public health challenges there is an ongoing reticence among many leading clinical journals to publish this research alongside trial findings.

SCT thus presents a unique opportunity to change the conversation about ART with young people. By specifically acknowledging adherence challenges in childhood and adolescence, if framed thoughtfully, healthcare staff can use SCT to show a greater contextual understanding about the reasons why and ways in which treatment can get disrupted. SCT could be used as a 'reward' for those who can manage to adhere well, sustaining them on the days 'on' ART, and/or an incentive for others to put more effort into taking treatment and lowering viral load.



Yet, thoughtful planning and framing of SCT to young people is necessary for these potential benefits to be realised. As a patient-managed strategy, participants felt that SCT could pose significant risk to other young people who may independently take treatment breaks under inappropriate conditions and without assessment and monitoring. This provides further evidence of the need for careful dissemination and communication post-trial.

The initial challenges described by so many participants need to be taken into serious consideration when planning any further intervention. The adaptation period, although different for different participants, was generally only short-lived but it should not be under-estimated. Our findings emphasise the importance of incorporating a package of interventions to accompany any roll-out of SCT to support young people in adapting to their new routine. We would anticipate that specific support should be provided for 12-16 weeks to accompany the adaptation period for those switching to SCT and that this should be preceded by a 2-4 week preparation period of education and counselling to alleviate concerns and ensure effective understanding about the weekend break. Participants also suggested that such an intervention during this period may be further strengthened by incorporating peer support from those already on SCT. Any intervention should be subject to ongoing evaluation. Provided early adjustments are carefully managed through a tailored brief support programme, the study has shown that SCT could be successfully transformed into a welcome treatment option for young people living with HIV.

**ACKNOWLEDGEMENTS**

The authors wish to thank all the participants in the study for the time and valuable information that they shared with us. We thank the BREATHER Clinical Trial Teams at the Clinical Trials Unit at University College London, for their significant contribution to this qualitative research. We also wish to acknowledge and thank our funders for their financial support.

**COMPETING INTERESTS**

The authors declare that they have no competing interests.

**FUNDING**

The BREATHER qualitative study was funded by the Economic and Social Research Council [RES-062-23-2308] and the NIHR Health Technology Assessment Programme [08/53/25]. The funders had no direct role in study design, data collection, analysis, interpretation, report writing, or the decision to submit for publication. The corresponding author had access to all data and responsibility for submission for publication.

**AUTHOR CONTRIBUTIONS**

SB was lead coordinator with oversight of all research activities was study. SB was co-investigator on the study with TR and JS. SB, TR and JS are guarantors for the study. SB led study design with contribution from all authors. SB and JS were responsible for study management. DG, PI for the clinical trial, coordinated between the qualitative sub-study team and the clinical trial team. SB directly carried out fieldwork in the US, UK and Ireland. SNK carried out fieldwork in Uganda. JS supervised the Uganda study site. SB, SP and SNK carried out the analysis. All

1  
2  
3 authors interpreted the results of the analysis. SB and SP prepared the first draft of  
4  
5 this paper. All authors reviewed manuscript drafts, revised for important intellectual  
6  
7 content, and approved the final version. All authors, external and internal, had full  
8  
9 access to all of the data in the study and can take responsibility for the integrity of  
10  
11 the data and the accuracy of the data analysis.  
12  
13

## 14 15 **ETHICAL APPROVAL**

16  
17  
18 The study obtained ethics approval from the following:

- 19  
20 • LSHTM Observational. Interventions Research Ethics Committee institutional  
21  
22 review -Ref- 5897. This covered all three sites, UK, Uganda and USA.  
23  
24
- 25 • The Medicines for Human Use (Clinical Trials) Regulations (MHRA)- Ref-  
26  
27 27505/0005/001-0005  
28
- 29 • National Research Ethics Service (REC), The Joint UCL/ UCLH Committees  
30  
31 on the Ethics of Human Research (Committee A)- Ref- 10/H0714/8  
32  
33
- 34 • The Uganda National Council for Science and Technology- Ref- SS-2641.  
35
- 36 • Joint Clinical Research Centre Ethics Committee no number (reference  
37  
38 JCRC-IRB/REC)  
39
- 40 • St Jude's Children's Research Hospital- Institutional Review Board 29.  
41  
42  
43  
44  
45

46  
47 All participants gave informed consent before taking part.

48  
49 The lead author (SB) affirms that the manuscript is an honest, accurate, and  
50  
51 transparent account of the study being reported; that no important aspects of the  
52  
53 study have been omitted; and that any discrepancies from the study as planned have  
54  
55 been explained.  
56  
57  
58  
59  
60

REFERENCES

1. Kim SH, Gerver SM, Fidler S, et al. Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. *Aids* 2014;**28**(13):1945-56

2. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, et al. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. *The Lancet Infectious Diseases* 2014;**14**(7):627-39

3. Vreeman RC, Gramelspacher AM, Gisore PO, et al. Disclosure of HIV status to children in resource-limited settings: a systematic review. *Journal of the International AIDS Society* 2013;**16**:18466

4. Bernays S, Jarrett P, Kranzer K, et al. Children growing up with HIV infection: the responsibility of success. *The Lancet* 2014;**383**(9925):1355-57 doi: 10.1016/s0140-6736(13)62328-4[published Online First: Epub Date]].

5. Bernays S, Paparini S, Seeley J, et al. 'Not taking it will just be like a sin': young people living with HIV and the stigmatisation of less-than-perfect adherence to antiretrovirals. *Medical Anthropology* 2016;**in press**

6. Bernays S, Seeley J, Rhodes T, et al. What am I 'living' with? Growing up with HIV in Uganda and Zimbabwe *Sociology of Health and Illness* 2015;**37**(2):270-83

7. Fielden SJ, Chapman GE, Cadell S. Managing stigma in adolescent HIV: silence, secrets and sanctioned spaces. *Culture, Health and Sexuality* 2011;**13**(3):267-81 doi: 10.1080/13691058.2010.525665[published Online First: Epub Date]].

8. Vreeman RC, Nyandiko WM, Ayaya SO, et al. The perceived impact of disclosure of pediatric HIV status on pediatric antiretroviral therapy adherence, child well-

- being, and social relationships in a resource-limited setting. *AIDS patient care and STDs* 2010;**24**(10):639-49
9. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. *Pediatrics* 2006;**118**(6):e1745-e57
10. Doherty K, Essajee S, Penazzato M, et al. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. *BMC Health Services Research* 2014;**14**(1):201
11. Haberer J, Mellins C. Pediatric adherence to HIV antiretroviral therapy. *Current HIV/AIDS Reports* 2009;**6**(4):194-200
12. MacDonell K, Naar-King S, Huszti H, et al. Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV. *AIDS and Behavior* 2013;**17**(1):86-93
13. Butler K, Inshaw J, Ford D, et al. BREATHER (PENTA 16) short-cycle therapy (SCT)(5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial. *Health Technology Assessment* 2016;**20**(49):1
14. The BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. *The Lancet HIV* 2016;**3**(9):e421-e30
15. Kippax S, Reis E, de Wit J. Two sides to the HIV prevention coin: efficacy and effectiveness. *AIDS Education and Prevention* 2011;**23**(5):393
16. Charmaz K. *Constructing Grounded Theory*. London: Sage, 2014.

17. Strauss AL, Corbin JM. *Grounded Theory Procedures and Techniques*. Newbury Park, California: Sage Publications, 1990.

18. Kawuma R, Bernays S, Siu G, et al. 'Children will always be children': Exploring perceptions and experiences of HIV-positive children who may not take their treatment and why they may not tell. *African Journal of AIDS Research* 2014;**13**(2):189-95

19. Bernays S, Paparini S, Gibb DM, et al. When information does not suffice: young people living with HIV and communication about ART adherence in the clinic. *Vulnerable Children and Youth Studies* 2016;**11**(1):60-68

20. Persson A, Newman C. Potency and vulnerability: Troubled 'selves' in the context of antiretroviral therapy. *Social Science and Medicine* 2006;**63**(6):1586-96

21. Al-Dakkak I, Patel S, McCann E, et al. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. *AIDS Care* 2013;**25**(4):400-14

## Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups

No	Item	Guide questions/description	Response	Page no.
<b>Domain 1: research team and reflexivity</b>				
Personal Characteristics				
1.	Interviewer/facilitator	Which author/s conducted the interview or focus group?	Stella Namukwaya; Sarah Bernays	9
2.	Credentials	What were the researcher's credentials? <i>E.g. PhD, MD</i>	BA, PhD	
3.	Occupation	What was their occupation at the time of the study?	Social Science Researchers	
4.	Gender	Was the researcher male or female?	Female	
5.	Experience and training	What experience or training did the researcher have?	15 years+ of social science data collection and analysis experience	
Relationship with participants				
6.	Relationship established	Was a relationship established prior to study commencement?	No	9
7.	Participant knowledge of the interviewer	What did the participants know about the researcher? <i>e.g. personal goals, reasons for doing the research</i>	As informed during consent process	8
8.	Interviewer characteristics	What characteristics were reported about the interviewer/facilitator? <i>e.g. Bias, assumptions, reasons and interests in the research topic</i>	As informed during consent process	8
<b>Domain 2: study design</b>				
Theoretical framework				
9.	Methodological orientation and Theory	What methodological orientation was stated to underpin the study? <i>e.g.</i>	Grounded analytic approach to	9



No	Item	Guide questions/description	Response	Page no.
		<i>grounded theory, discourse analysis, ethnography, phenomenology, content analysis</i>	qualitative thematic analysis	
	Participant selection			
10.	Sampling	How were participants selected? <i>e.g. purposive, convenience, consecutive, snowball</i>	purposive	10
11.	Method of approach	How were participants approached? <i>e.g. face-to-face, telephone, mail, email</i>	Face-to-face	8-9
12.	Sample size	How many participants were in the study?	43	10
13.	Non-participation	How many people refused to participate or dropped out? Reasons?	None dropped out	10
	Setting			
14.	Setting of data collection	Where was the data collected? <i>e.g. home, clinic, workplace</i>	Clinic and home	9
15.	Presence of non-participants	Was anyone else present besides the participants and researchers?	no	
16.	Description of sample	What are the important characteristics of the sample? <i>e.g. demographic data, date</i>	Sex, age, ethnicity, trial arm	10-11
	Data collection			
17.	Interview guide	Were questions, prompts, guides provided by the authors? Was it pilot tested?	No	
18.	Repeat interviews	Were repeat interviews carried out? If yes, how many?	Up to 3 times	10
19.	Audio/visual recording	Did the research use audio or visual recording to collect the data?	yes	9
20.	Field notes	Were field notes made during and/or after the interview or focus group?	yes	
21.	Duration	What was the duration of the interviews or focus group?	45-120 mins	9
22.	Data saturation	Was data saturation discussed?	Yes	10
23.	Transcripts returned	Were transcripts returned to participants for comment	No	



No	Item	Guide questions/description	Response	Page no.
		and/or correction?		
<b>Domain 3: analysis and findings</b>				
Data analysis				
24.	Number of data coders	How many data coders coded the data?	3	9
25.	Description of the coding tree	Did authors provide a description of the coding tree?	No	
26.	Derivation of themes	Were themes identified in advance or derived from the data?	Derived from the data	9
27.	Software	What software, if applicable, was used to manage the data?	None	
28.	Participant checking	Did participants provide feedback on the findings?	Yes, in a focus group	9
Reporting				
29.	Quotations presented	Were participant quotations presented to illustrate the themes / findings? Was each quotation identified? e.g. <i>participant number</i>	Yes; yes	Multiple pages
30.	Data and findings consistent	Was there consistency between the data presented and the findings?	Yes	
31.	Clarity of major themes	Were major themes clearly presented in the findings?	Yes	
32.	Clarity of minor themes	Is there a description of diverse cases or discussion of minor themes?	Yes	